Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass

Eur J Cardiothorac Surg. 2009 Oct;36(4):657-64. doi: 10.1016/j.ejcts.2009.03.065. Epub 2009 Jun 11.

Abstract

Objectives: Phosphodiesterase-5 inhibitors and elevated myocardial cyclic guanosine monophosphate levels can induce potent cardioprotection-like effects against ischaemia-reperfusion injury. We investigated the effects of vardenafil, a selective phosphodiesterase-5 inhibitor on myocardial and endothelial functions during reperfusion in a canine model of cardioplegic arrest and extracorporal circulation.

Methods: Vehicle-treated (control, n=8) and vardenafil-treated (30 microgkg(-1) intravenous (IV); n=8) anaesthetised dogs underwent hypothermic cardiopulmonary bypass with 60 min of hypothermic cardiac arrest. Left and right ventricular end-systolic pressure volume relationship (E(es)) was measured by a combined pressure-volume conductance catheter at baseline and after 60 min of reperfusion. Left anterior descending coronary blood flow and endothelium-dependent vasodilatation to acetylcholine were determined. Isolated coronary arterial rings were investigated for vasomotor function using an in vitro organ bath system.

Results: Pharmacological preconditioning with vardenafil led to significantly higher plasma cyclic guanosine monophosphate levels and myocardial adenosine triphosphate content to a better recovery of left and right ventricular E(es) (Delta left ventricular E(es) given as percent of baseline: 74.2+/-4.5% vs 50.4+/-5.0%, p<0.05) and to a higher coronary blood flow (58+/-12 vs 24+/-7 mlmin(-1), p<0.05). Endothelium-dependent vasodilatory responses to acetylcholine - measured both in vivo and in vitro - were improved in the vardenafil group.

Conclusions: Application of vardenafil improves myocardial and endothelial functions after cardiopulmonary bypass with hypothermic cardiac arrest. The observed protective effects imply that phosphodiesterase-5 inhibition could be a novel therapeutic option in the protection against ischaemia-reperfusion injury in cardiac surgery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Cardiopulmonary Bypass / adverse effects*
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use*
  • Cyclic GMP / blood
  • Disease Models, Animal
  • Dogs
  • Drug Evaluation, Preclinical / methods
  • Endothelium, Vascular / physiopathology
  • Hemodynamics / drug effects
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Ischemic Preconditioning, Myocardial / methods
  • Myocardial Reperfusion Injury / etiology
  • Myocardial Reperfusion Injury / prevention & control*
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Preanesthetic Medication
  • Sulfones / pharmacology
  • Sulfones / therapeutic use
  • Triazines / pharmacology
  • Triazines / therapeutic use
  • Vardenafil Dihydrochloride
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Right / drug effects

Substances

  • Cardiotonic Agents
  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • Adenosine Triphosphate
  • Cyclic GMP